EUCTR2007-004350-82-LT进行中（未招募）不适用
Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome
undbeck Inc0 个研究点目标入组 304 人开始时间: 2008年1月21日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 304
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) The subject or subject’s LAR must sign and date the IRB/IEC approved Informed Consent Form/HIPAA Authorization (if required) prior to study participation.
- •2) Previous participation in Ovation-sponsored LGS study.
- •3) Subject must weigh greater or equal 12.5 kilograms.
- •4) Male or female subjects must have been between 2 and 60 years of age at the time of the enrollment in the Phase 3 double-blind study (protocol number OV-1012) or between 2 and 30 years of age at the time of the enrollment in the Phase 2 double-blind study (protocol number OV-1002) study.
- •5) If female:
- •a. Subject is either not of childbearing potential, defined as premenarchal, postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with a method of birth control acceptable to the investigator during the study, for at least 4 weeks prior to study entry and for 4 weeks following completion of the study.
- •b. Subject is not breastfeeding.
- •c. Subjects of childbearing potential must have a negative serum pregnancy test at Study Day 1.
- •6) In the investigator’s opinion, parent or caregiver must be able to keep an accurate seizure diary.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Greater than 14 days have elapsed since the subject received his/her last dose of study medication in the previous Ovation-sponsored LGS study.
- •2) Subject had a serious or severe adverse event in the previous Ovation sponsored LGS study that in the opinion of the investigator was probably or definitely related to clobazam use and precludes safe use of clobazam.
- •3) Subject has had an anoxic episode requiring resuscitation within 6 months of study entry.
- •4) Subject has a history of an allergic reaction or significant sensitivity to benzodiazepines or to any of the other ingredients in clobazam tablets.
- •5) Subject is taking more than 3 concurrent AEDs. NOTE: Vagal Nerve Stimulator (VNS) or ketogenic diet is allowed and will not be counted in the three allowed AEDs.
- •6) Subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for idiopathic nephrotic syndrome or asthma.
- •7) If the subject is taking felbamate, has been taking it for less than 1 year prior to study entry or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events.
- •8) Subject has experienced an idiosyncratic reaction to an AED, e.g., carbamazepine with resulting aplastic anemia or agranulocytosis, topiramate with resulting metabolic acidosis, felbamate with resulting aplastic anemia or hepatic failure, or lamotrigine with resulting skin irritation and/or rash.
- •9) Subject has shown any clinically significant history of hyper-sensitivity to CNS-active medications leading to neurobehavioral aberrations (e.g., increased biting, scratching, kicking, or hitting).
- •10) Subject has taken or used any investigational drug or device in the 30 days prior to screening, with the exception of clobazam in an Ovation-sponsored study.
- •11) Subject has a clinically significant unstable hepatic, hematological, renal, cardiovascular, gastrointestinal, or pulmonary disease or ongoing malignancy.
- •12) Subject has a diagnosis of sleep apnea.
- •13) Subject has a compromised respiratory function or severe respiratory insufficiency.
- •14) Subject has a history of severe muscle weakness, including myasthenia gravis.
- •15) Subject has a clinically significant abnormal laboratory value or electrocardiogram (ECG) abnormality.
- •16) Subject has progressive lesion confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
- •17) Subject has a history of drug or alcohol abuse.
- •18) Subject has a history of poor compliance on past antiepileptic therapy.
- •19) Subject has inadequate supervision by parent or guardian.
- •20) For any reason, the subject is considered by the investigator to be an unsuitable candidate for the study.
研究者
相似试验
进行中（未招募）
不适用
Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut SyndromeEUCTR2007-004350-82-BGOvation Pharmaceuticals304
已完成
3 期
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut SyndromeLennox-Gastaut SyndromeNCT01160770Lundbeck LLC267
招募中
3 期
"Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures "2023-506841-52-00Sk Life Science Inc.74
进行中（未招募）
1 期
Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) SeizuresPartial onset (focal) seizuresMedDRA version: 26.1Level: LLTClassification code 10016843Term: Focal seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10061334Term: Partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10039910Term: SeizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-005344-27-PLSK Life Science, Inc.140
进行中（未招募）
1 期
Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizurespartial onset (focal) seizuresMedDRA version: 21.1Level: LLTClassification code 10016843Term: Focal seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10061334Term: Partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10039910Term: SeizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-005344-27-ESSK Life Science, Inc.140